Skip to main content

Bristol Myers doubles down on Immatics with new $770M biobucks collab for solid tumor bispecific: Fiercebiotech

 Bristol Myers Squibb is doubling down on Immatics with $150 million upfront to get access to a preclinical bispecific targeting solid tumors.

This will be the pair's second collaboration, technically speaking. Immatics inked a deal with Celgene in August 2019 prior to its acquisition by BMS. That collaboration is focused on T-cell therapies for solid tumors and is still in the preclinical phase.

Now, BMS is putting up $150 million and could dole out up to another $770 million in biobucks to the German biotech to license, develop and commercialize a T cell-redirecting, or TCR, bispecific, the companies said Tuesday. Immatics asked German regulators last month to approve a clinical trial of the drug, dubbed IMA401, in various solid tumors that is slated to begin in the first half of next year.


Immatics retains the option to co-fund U.S. development of IMA401 in return for enhanced U.S. royalty payments and/or will co-promote the medicine in the U.S. 

The bispecific, as its name suggests, has two core goals: One binding region targets melanoma-associated antigen 4 and/or 8 (MAGEA4/8), and the other region aims to engage and activate T cells. MAGEA4/8 is prevalent in a slate of solid tumors across the lungs, head and neck, bladder and uterus, among other areas of the body.


IMA401 is the most advanced therapy in Immatics' TCR bispecific pipeline, the biotech said. These therapies have a "cell therapy-like efficacy in an off-the-shelf platform," according to BMS' Teri Foy, Ph.D., senior vice president of research and early development for immuno-oncology and cell therapy. 

In preclinical studies, IMA401 showed anti-tumor activity, according to Immatics. Under the deal, the two companies will collaborate on clinical development. 

The Big Pharma tie-up comes a month after Immatics released data on the TCR-engineered cell therapy IMA203 that showed responses in 50% of heavily pretreated patients. But many patients saw their cancer come back within weeks, which means Immatics need to improve durability to have a shot at the market


https://www.fiercebiotech.com/biotech/immatics-inks-new-770m-biobucks-collab-bristol-myers-for-preclinical-solid-tumor-bispecific


Comments

Post a Comment

Popular posts from this blog

Can We Make A Vaccine Against Smoking?

  This segment sounds good but we need to be careful here or we end up where we started in 2021 vaccines becoming political. 
Post a Comment
Read more

Texas governor bans vaccine passports from being required in state ABC News

  Thats Right States like Texas and Florida got the Vaccine Passport Conspiracy from Del Bigtree.  https://abc7.com/politics/texas-governor-bans-vaccine-passport-requirement-in-state/10491161/ AUSTIN, Texas -- Gov. Greg Abbott issued an executive order Tuesday morning prohibiting state agencies or political subdivisions in Texas from creating a "vaccine passport" requirement. Conversation has grown around  vaccine passports recently as an option that can be used for travel or even eating out . They are typically described as an app with a code that verifies if someone has been vaccinated or recently tested negative for COVID-19. They're already in use in Israel, and in development in parts of Europe. But Abbott shut that down as an option in the Lone Star State with Executive Order No. GA - 35 also prohibiting "organizations receiving public funds from requiring consumers to provide documentation of vaccine status in order to receive any service or enter any place....
Post a Comment
Read more

Anti-Vax Conspiracies strike back in the USA July 2021 Original Article

 Thumbnail credit by Jeff Holiday Production In the past few weeks the anti-vax lobby has ratcheted up the ante on their lobbying efforts. The event that kicked off this new wave of anti-vax scares was the "Knock on the Door rants" according to the Washington Post on a July 9th article they cited  rants by Marjorie Taylor Greene and Laurent Boebert in a political rally that sparked the scare. "Rep. Marjorie Taylor Greene (R-Ga.) got the ball rolling Tuesday by comparing the effort to “ medical brown shirts showing up at their door ordering vaccinations .” Not to be outdone, Rep. Lauren Boebert (R-Colo.) took to Twitter the next day to offer her own Nazi comparison, labeling the door-knockers “ needle Nazis .” If anyone should know the folly of such metaphors, it would seem to be Greene, who just three weeks prior conceded in an apology after another wayward Nazi/coronavirus comment that “ there is no comparison to the Holocaust .” And it’s worth emphasizing that there is...
Post a Comment
Read more